Daily Watch List: Nova Measuring Instruments (NASDAQ:NVMI), Conns Inc. (NASDAQ:CONN), Lakeland Industries Inc. (NASDAQ:LAKE), Regeneron Pharmaceuticals (NASDAQ:REGN), Alexion Pharmaceuticals (NASDAQ:ALXN)


Nova Measuring Instruments Ltd. (NASDAQ:NVMI) on Tuesday reported second-quarter net income of $2.2 million. On a per-share basis, the Ness-Ziona, Israel-based company said it had net income of 8 cents. Earnings, adjusted for one-time gains and costs, came to 20 cents per share. The maker of monitoring systems used in chip manufacturing posted revenue of $40.6 million in the period. Nova Measuring Instruments Ltd. (NASDAQ:NVMI) shares moved up 1.56% in last trading session and ended the day at $12.36. NVMI Gross Margin is 53.20% and its has a return on assets of 8.80%. Nova Measuring Instruments Ltd. (NASDAQ:NVMI) quarterly performance is 8.52%.

Conns Inc. (NASDAQ:CONN) ended the last trading day at $34.74. Company weekly volatility is calculated as 5.84% and price to cash ratio as 252.98. Conns Inc. (NASDAQ:CONN) showed a weekly performance of -10.30%.

On July 23, Lakeland Industries Inc. (NASDAQ:LAKE) announced that Gary Pokrassa has retired as Chief Financial Officer. Teri W. Hunt, a 10 year veteran of Lakeland and most recently serving as Vice President of Finance based in the Company’s Decatur, Alabama offices, has been named as Acting Chief Financial Officer, effective July 17, 2015, to succeed Mr. Pokrassa. In order to facilitate a smooth succession, Mr. Pokrassa has agreed to continue with the Company in a consulting capacity for a period of one year. On 29 July, Lakeland Industries Inc. (NASDAQ:LAKE) shares moved up 0.70% and was closed at $10.05. LAKE EPS growth in last 5 year was 31.40%. Lakeland Industries Inc. (NASDAQ:LAKE) year to date (YTD) performance is 7.26%.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. As part of the agreement, the two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in Phase 1 testing and plan to initiate clinical trials in 2016 with new therapeutic candidates based on ongoing, innovative preclinical programs. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares moved down -1.12% in last trading session and ended the day at $546.27. REGN Gross Margin is 92.00% and its has a return on assets of 9.40%. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) quarterly performance is 16.30%.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on Thursday reported second-quarter net income of $170.2 million. On a per-share basis, the Cheshire, Connecticut-based company said it had net income of 83 cents. Earnings, adjusted for stock option expense and costs related to mergers and acquisitions, came to $1.44 per share. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) caters to the Healthcare space. It has a net profit margin of 26.00% and weekly performance is -3.59%. On the last day of trading company shares ended up $198.76. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) distance from 50-day simple moving average (SMA50) is 9.55%.


Leave a Reply

Your email address will not be published. Required fields are marked *